Patent ID: 7605123

Claim:
A water soluble solid pharmaceutical composition formulated for oral administration by ingestion, comprising: (a) from about 5 to about 65% w/w of a salt of a fatty acid component, where the salt of a fatty acid component comprises saturated or unsaturated C 4 , C 5 , C 6 , C 7 , C 8 , C 9 , C 10 , C 11 , or C 12 fatty acids; and (b) an insulin compound conjugate comprising an insulin protein coupled to a modifying moiety having a formula: —X—R 1 —Y-PAG-Z-R 2 (Formula VI) where, X, Y and Z are independently selected linking groups and each is optionally present, and X, when present, is coupled to the insulin compound by a covalent bond, wherein the linking group is selected from —C(O)—, —O—, —S—, —C— and —N—, R 1 , if present, is a lower alkyl and may optionally include a carbonyl group; R 2 is selected from the group consisting of a lower alkyl, optionally including a carbonyl group, and a capping group selected from the group consisting of —CH 3 , —H, tosylate, branched or linear C 1-6 and an activating group, wherein when R 1 present, R 2 is a member of the capping group; and PAG is a linear or branched carbon chain incorporating one or more polyethylene glycol moieties, and optionally incorporating one or more additional moieties selected from the group consisting of —S—, —O—, —N—, and —C(O)—; and an enteric coating material for coating of the water soluble solid composition fabricated into a solid form to survive passage through the stomach without substantial loss of the insulin protein.